Bottom line
GTHRX vs PRHSX: the short answer
GTHRX (INVESCO Health Care Fund) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both mutual funds.
But PRHSX is far broader, holding 279 positions to 82 for GTHRX, so beyond the top names it adds exposure GTHRX doesn't have.
PRHSX is cheaper at 0.83% vs 1.32% — a difference of $49 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +3.5% for GTHRX.
Updated Nov 19, 2026
GTHRX vs PRHSX side by side
| GTHRX | PRHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Invesco | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.32% | 0.83% |
| Annual cost per $10k | $132 | $83 |
| 10-yr cost on $10k (prospectus) | $1,590 | $1,025 |
| Max front load | 0% | — |
| 12b-1 fee | 0.5% | — |
| 1-yr return | +15.2% | +17.7% |
| 5-yr return (annualized) | +3.5% | +4.2% |
| 10-yr return (annualized) | +6.1% | +9.1% |
| Best quarter | +19.6% | +23.5% |
| Worst quarter | −16.5% | −15.8% |
| Net assets (fund) | $1.2B | $11.9B |
| Number of holdings | 82 | 279 |
| Portfolio turnover | 59% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GTHRX | PRHSX | Difference |
|---|---|---|---|
| 2024 | +4.0% | +1.8% | +2.2% |
| 2023 | +3.1% | +3.1% | −0.0% |
| 2022 | −13.5% | −12.2% | −1.3% |
| 2021 | +12.2% | +13.3% | −1.1% |
| 2020 | +14.5% | +30.1% | −15.7% |
| 2019 | +32.0% | +29.1% | +2.9% |
| 2018 | +0.5% | +1.2% | −0.8% |
| 2017 | +15.5% | +28.0% | −12.5% |
| 2016 | −11.7% | −10.4% | −1.4% |
Source: Fund prospectus bar charts
Holdings overlap
12 of GTHRX's top 25 holdings also appear in PRHSX's top 25.
| Holding | GTHRX | PRHSX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 14.28% |
| Johnson & Johnson | 6.76% | 6.63% |
| UnitedHealth Group Inc. | 6.17% | 5.99% |
| Merck & Co., Inc. | 4.59% | 4.01% |
| AbbVie Inc. | 4.03% | 5.10% |
| Gilead Sciences, Inc. | 3.63% | 2.82% |
| CVS Health Corp. | 2.52% | 0.94% |
| BrightSpring Health Services, Inc. | 2.20% | 0.82% |
| Cardinal Health, Inc. | 2.10% | 1.03% |
| Guardant Health, Inc. | 2.04% | 1.23% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.28% |
| Thermo Fisher Scientific Inc. | 1.55% | 2.52% |
Source: SEC Form N-PORT
GTHRX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between GTHRX and PRHSX?
Which is cheaper, GTHRX or PRHSX?
Should I own both GTHRX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.